TABLE 3.
Frequency of amino acids in HIV-2 protease, from untreated and PI-containing-regimen-treated patients, at positions suspected of being associated with resistance to PI
| Virus | HIV-2 protease amino acid at positiona:
|
|||||
|---|---|---|---|---|---|---|
| 7 | 46 | 62 | 71 | 90 | 99 | |
| Wild-type HIV-1b | Q | M | I | A | L | F |
| HIV-2 subtype A (consensus sequence)c | K (N) | I (V) | V (I) | V | L | L |
| HIV-2 subtype B (consensus sequence)c | R | I | V | V | L | F |
| HIV-2 strains from patients with no antiretroviral therapy | K (100) | I (59), V (35), T (6) | V (94), I (6) | V (94), I (6) | L (100) | L (88), F (12) |
| HIV-2 strains from patients receiving PI-containing anti- retroviral therapy | K (70), R (11), K/R (7), K/Q (4), K/E (4), Q (4) | I (96), V/I (4) | V (63), A (19), T (11), V/A (7) | I (52), V (41), V/I (7) | L (70), M (26), L/M (4) | F (48), L (48), L/F (4) |
a
Below each amino acid position is the list of amino acids that are observed, and in parentheses is the percentage of sequences concerned. The predominant amino acid for each position is given first. Amino acids found to be selected by PI-containing antiretroviral therapy are in bold type.
b
Wild-type sequence from the reference HIV-1 strain HXB2 (GenBank accession number K03455).
c
Available at http://hiv-web.lanl.gov/content/hiv-db/ALIGN_CURRENT/ALIGN-INDEX.html; nonpredominant amino acids are indicated in parentheses.